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ABSTRACT 
We introduce a superstatistical model for the progression statistics of malignant cancer cells. The 
metastatic cascade is modeled as a complex nonequilibrium system with several macroscopic 
pathways and inverse-chi-square distributed parameters of the underlying Poisson processes. The 
predictions of the model are in excellent agreement with observed survival time probability 
distributions of breast cancer patients. 
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Introduction 
Although cancer is a remarkably diverse class of diseases at the genetic level, the similarities become 
more apparent as we move up the hierarchy of organization. At the highest somatic level, invasion 
of normal tissue, either adjacent or distant, is essentially the singular means by which cancer realizes 
its malevolent agenda. The degree to which it is able to carry this out is a function of the states of all 
the systems lesser in scope. For example, the ability for a cancerous cell to invade is dependent upon 
certain phenotypic characteristics such as its motile and migratory ability, which is in turn dependent 
on characteristics such as ability to degrade the extracellular matrix, in turn dependent on relative 
expression levels of molecules such as matrix metalloproteinases, which is ultimately determined by 
aberrations in the genetic code. Furthermore, complex epigenetic, evolutionary, and 
microenvironmental forces act at various levels to help create a complex, highly nonlinear spatially 
extended dynamical system.  
 
Metastasis is the formation of secondary tumors derived from cells from a malignant primary tumor, 
and is deadly despite being a highly inefficient process. From a clinical perspective, this inefficiency 
also makes it an elusive process, as millions of cells are required to disseminate to allow for the 
selection of cells aggressive enough to survive the metastatic cascade. This cascade is a series of 
sequential steps, which include the shedding of cells directly into the circulatory system or indirectly 
via the lymphatic system, survival within the circulation to arrest in a new organ site, extravasation 
into the new surrounding tissue to initiate growth, and finally induction of angiogenesis to maintain 
that growth. For a single cell in the primary tumor, metastasis is inherently a stochastic process. This 
process is driven by an underlying phenotype, resulting in statistical distributions characterized by 
that phenotype. This distribution starts out being uniformly zero for the case of a cell existing within 
in situ disease. As the accumulation of genetic mutations lead to the acquisition of invasion and 
migratory mechanisms, this distribution becomes non-zero, and evolves temporally as the 
acquisition and strengthening of additional mechanisms proceed. Because the stromal 
microenvironment imposes a selective pressure as well, this distribution can be expected to evolve 
spatially with respect to cell-microenvironment interaction dynamics.  
 
There has been increasing interest in mathematical modeling of the processes of cancer progression 
at all different levels, from the theoretical aspects of somatic evolution and its role in carcinogenesis 
[1-3], to the experimentally validated models of tumor growth and invasion [4-7], to the 
characteristics of metastatic disease [8-11]. Here, we are concerned with modeling cancer survival, 
which, as will be explained later, comes out of modeling metastasis. 
 
The model presented here places cancer in the context of a complex nonequilibrium system, and it 
will be discussed how such a model may generate some insight into the mechanisms of metastasis. 
Additionally, its potential practical applications in survival analysis are briefly mentioned. Our model 
is based on superstastical techniques, which are quite frequently used in nonequilibrium statistical 
mechanics to model complex systems with spatial inhomogenities [19-21]. To the best of our 
knowledge, the application described here is the first application of superstatistics in medicine, and it 
is also the first application of a particular class of superstatistics, so-called inverse-chi-square 
superstatistics. 
 
 
Data 
The Surveillance, Epidemiology, and End Results (SEER) database of the US National Cancer 
Institute was used [12, 13]. Only breast cancer is considered here, which constitutes 717,810 patients 
diagnosed from 1973 – 2003. Relevant information such as survival time, cause of death, tumor size, 
histological type, etc. were extracted. Follow-up and accuracy of information is not 100%, but the 
advantage is clearly its sheer size.   
 
The challenges of developing an accurate theoretical model from experimental analysis are 
exacerbated by the incredible complexity of the biological system being modeled. Indeed, this is true 
for any biological system, but it is especially true for cancer systems, due to their multiple levels of 
organization, heterogeneity from patient to patient as well as within the same patient, and of the 
number of processes involved. For modeling metastases especially, one needs a large experimental 
dataset to reduce fluctuations to a minimum, and to allow for the characterization of truly 
macroscopic behaviors. Therefore, the SEER database is an invaluable resource in this regard.  
 
All patients that are marked as having survival time less than 6 months are excluded from analysis, 
because the survival time for these patients may not accurately reflect the assumptions of our model. 
The model is based upon the progression of the metastatic cascade, having undergone treatment in 
the form of surgery, chemotherapy, or radiation. Although treatment is not explicitly addressed, it is 
assumed, and acts as another source of heterogeneity in the model. The arbitrary limit of 6 months 
significantly diminishes the population for whom treatment was delayed, and those who presented 
with metastatic disease at the time of diagnosis. For patients recorded as having a survival time of 
zero, results were most likely determined at autopsy, and it is thus not necessarily the case that they 
died within one month of diagnosis (the resolution of the data).  
 
 
The Model 
In over 90% of cancer patients, it is the proliferation of distant metastases that ultimately induce 
death, and not the primary tumor [14]. Of the remaining 10%, most, if not all, presumably die from 
some form of recurrence, or failure of primary treatment. Therefore, death can be thought of as the 
end result of a multiple events of spread, each event characterized by multiple branches, where each 
branch can be theoretically traced to a progenitor cell in the primary tumor. These progenitor cells 
can be characterized by the time progressed until it, or any cell the progenitor cells give rise to, 
becomes a participant in the final events of death. Intuitively, these branches may be thought of as 
steps in the sequence of events characterizing the progression of cancer leading to death. However, 
the premise here is that these branches can be eliminated from the model by characterizing only the 
progenitor cells. 
 
Distant metastases may arise through one of two pathways – through the lymphatic system or the 
vascular system [15]. There is extensive data indicating that hematagenous metastases and lymphatic 
metastases obey different statistics [16]. Cancer cells can disseminate from the primary tumor to 
local lymph nodes, proliferating into micrometastases in these nodes, and then subsequently 
spreading to distant sites. Alternatively, cancer cells can simply intravasate directly into the 
bloodstream and end up at distant sites, some surviving to form metastases. Because these two 
models are complementary to one another, it is assumed that both are occurring to give rise to 
distant metastases. The extent of the utilization of either pathway varies among cancer types. For 
example, in the case of breast carcinoma, lymphatic invasion is thought to be the most significant 
pathway in mid-stage disease, due to the extensive presence of lymphatics [17]. It is thought that the 
lymph node environment then further selects for more aggressive phenotypes, and the cancer more 
easily invades distant organs. Of course, in breast cancer as well as other cancers, these pathways are 
by no means sequential or linear. The simplified process is shown in Figure 1.
 
 
Figure 1. Macroscopic pathways of the metastatic cascade. 
 
Let T be the survival time of a patient. From the definition above, it follows that T is the waiting 
time until n events of spread have given rise to the collection of metastases present upon death. 
Each event of spread is an exponentially distributed random variable, assuming it follows a Poisson 
process. For n exponentially distributed random variables with rate λ, T follows the gamma 
distribution [18]: 
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where qualitatively,  controls the shape and 1≥n 0≥λ  adjusts the scale. 
 
Because we are interested in survival, we consider spread events in the macroscopic sense – those 
that are the precursors to death. There can be any number of spread events, but due to both physical 
and biological correlations for each pathway of spread, the number of events n can be effectively 
reduced to an effective dimension of the network of pathways of spread. n thus represents the 
effective degrees of freedom in Eq. (1). These degrees of freedom are represented by the pathways 
represented by the solid lines in Figure 1.  
 
However, there are also higher-order pathways in this basic model. For example, cancer cells can 
spread from one node to other nodes, and cells within distant metastases can even detach and form 
new metastases [15]. These pathways are shown with the dashed arrows. Fractal properties then 
emerge within the pathway network, so the effective degrees of freedom for this spread network 
need not be an integer, and in fact should be greater than 3. However, if a patient’s cancer is at a 
more advanced stage, the effective degrees of freedom should decrease, as the pathways for spread 
essentially “close off”. For example, if a patient presents with nodal metastases, then the pathway 
from the primary site to the lymph nodes becomes less significant. Random networks in the 
superstatistical context have also been discussed in [38].    
 
λ is an intensive parameter of the cancer system, measuring its intrinsic aggressiveness or 
invasiveness. However, as a complex non-equilibrium system, dynamical behavior at various 
microscopic levels will cause spatio-temporal fluctuations in this parameter. It is important to note 
that this is a function of both a cancerous cell itself as well as its interaction with its surrounding 
environment. The assumption of superstatistical models is that the system can be partitioned such 
that each partition will be in local equilibrium, following Boltzmann-Gibbs statistics locally [19-21]. 
Globally, the system can then be described by a superstatistics, which is a superpositioning of the 
local statistics of these various partitions each with its own characteristic intensive parameter.  
Here we generalize this concept to applications in medicine, in particular to the process of 
metastasis. 
 
The fluctuations in the intensive parameter can be characterized by subordinate processes. For a 
macroscopic spread event (i.e., an event that ultimately contributes to death), let us assume that 
there are s participating cells. Each cell will perform a diffusion process. For a diffusion process 
the mean square displacement grows linearly in time t, 
 
Dtx =2 , (2) 
 
where D is the diffusion constant. Hence, to travel a typical distance d, the corresponding  
typical time duration satisfies 
 
( ) 21Dtd = . (3) 
 
For the spread events, we assume that there are s random variables ξi that are approximately 
independent, each corresponding to the square root of the spread time 21t for the ith cell. This is 
illustrated in Figure 2.  
  
Figure 2. Macroscopic spread events for a degree-of-freedom j, which comprises of s participating 
progenitor cells. 
 
The assumption of independence is valid because the length of time two cells share the same 
environment is negligibly small. Two cells within the primary tumor can reside within close 
proximity of one another, and thus their movement may be correlated [22], but as soon as one cell 
intravasates, they no longer share a single microenvironment. Because a participating cell is defined 
as one that ultimately contributes to a spread event, it must survive the entire metastatic process, and 
the time spent at the primary site for these cells is only but a sliver of the metastatic cascade 
timescale, as it becomes increasingly more difficult to survive within the vasculature and eventually 
the ectopic host microenvironment after extravasation. It then follows that these random variables 
are additive, and as such, the sum of these random variables will tend to a Gaussian [21]: 
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where Xj is a random variable corresponding to the jth degree of freedom in the network of possible 
paths, ],1[ nj ∈ .  
                                                           
Therefore, λ1 , the expected time to spread, which is the sum of the squared Gaussian random 
variables , is χ2jX 2 distributed, and λ, the rate of spread, is inverse-χ2 distributed, with degrees of 
freedom equal to n:  
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This accounts for fluctuations among different degrees of freedom, or pathways of spread. For 
example, some patients may present with extensive distant disease without any positive lymph 
nodes, while others will have micrometastases that remain dormant for extended periods of time 
[15, 23, 24]. 
 
To find the probability density function of survival times, we multiple the expressions in Eqs. (1) 
and (5) and integrate over all possible λ: 
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obtaining: 
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where  is the modified Bessel function of the second kind of order υ. )(zK υ
 
Because the model is of cancer-specific death, this probability density function is conditional upon 
death from cancer. One can imagine many other possible causes of death, any one of which may 
occur before the time of death which would have been the result of cancer alone. This is simply due 
to the stochastic nature of cancer progression, the complex dynamics of comorbidities, and chance 
events such as accidents. Therefore, this does not model the survival of cancer in the traditional 
overall sense, but rather finds the time distribution of disease-specific risk. 
 
 
Asymptotic behaviors 
It should be noted that the probability density function for λ (Eq. (5)) generates the asymptotic form  
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for 0→λ . Using Eq. (8), we can then derive the asymptotic behavior of )(tf  as ∞→t . The 
behavior for large times is determined entirely by the behavior for partitions of the system with low 
rates of metastasis. Rearranging Eq. (6) such that we can apply Laplace’s method [25, 26], we have: 
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The approximation of this integral for large t gives 
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where λˆ is the value of λ that maximizes the exponential, which equals: 
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Thus, we obtain the following for the numerator and denominator of Eq. (10): 
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Substituting (12) and (13) back into (10), it is found that as ∞→t , )(tf  behaves as: 
 ( ) ( )tbtbttf a −− exp~exp~)(  (14) 
 
(see also [26]). 
 
We can also determine the asymptotic behavior of the system as a function of its size. Let us define 
a parameter λNθ =  where N is the number of cancerous cells. Since the expected time 1/λ to 
spread decreases as the number of cells N increases, we may assume that λNθ =  is constant or 
nearly constant. In our model, λ1  is distributed according to a χ2 distribution, meaning 
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Therefore, as ∞→λ , the probability density of λ1  decays as a power law. 
 
If the probability of spread as a function of cell number )(Nf  also behaves as a power law for large 
N, 
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then due to proportionality ( λNθ =  constant) we have 
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In a study of the relationship between metastasis probabilities and tumor size [27], it was observed 
that the per-cell probability of lethal spread of breast cancer and melanoma cells as a function of the 
number of cells in the tumor displayed a remarkable abidance to a power law. The number of cells 
for a tumor was extrapolated from its clinical size (roughly the diameter, assuming spherical 
geometry) at diagnosis, but the fit is unquestionable, with melanoma decaying as  and 
breast cancer as , where N is the number of cells. Using Eq. 
7836.0~ −N
5611.0~ −N (17), it can then be predicted 
that n should be on the order of 3.567 for melanoma and 3.122 for breast cancer. In the next 
section, we see that these values are in agreement with parameters obtained from survival 
distribution fits. 
 
 
Distribution Fits 
Using a simple genetic algorithm method, parameters were obtained for a few breast cancer 
subpopulations. The objective fitness function is a sum of weighted least squares, with the weights 
counterbalancing the increasing variance at longer times due to the increasing sparseness of data. 
First, fitting the model to the entire breast cancer population gives parameter values of  
and . The fitted curve as given by Eq. (7) together with the data is plotted in 
00004.3=n
08712.00 =λ Figure 3.
Excellent agreement is obtained. 
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Figure 3. All breast cancer-specific death data (red) and best-fit model (blue): 00004.3=n  
and 08712.00 =λ . 
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(a) 0-2cm size group
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Figure 4. Breast cancer-specific death data divided into comparable-size population groups based on 
tumor diameter (red) and best-fit models for each (blue). 
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Figure 5. Breast cancer-specific death data of the two most common histological types (red) and 
best-fit models for each (blue). 
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Figure 6. Breast cancer-specific death data divided into different population groups based on 
pathological grade. 
 
Table 1. Summary of parameters for best-fit superstatistics model of various breast cancer 
populations. 
Population group Number of 
patients 
n λ0 R2
All 78,779 3.00004 0.08712 0.996 
Size: 0-2cm 19,439 3.40346 0.07721 0.987 
Size: 2-3cm 20,435 3.32542 0.08605 0.989 
Size: 3-5cm 22,004 3.21949 0.09827 0.989 
Size: >5cm 16,793 2.58853 0.11877 0.990 
Histology: ductal 58,398 3.13148 0.08982 0.996 
Histology: lobular 5,287 3.07063 0.07370 0.954 
Grade: 1 1,815 2.89975 0.08092 0.885 
Grade: 2 12,586 3.34077 0.09201 0.982 
Grade: 3 24,544 3.51748 0.13387 0.992 
 
Tab. 1 and Figs. 4-7 show the best-fit models for different sub-populations. Because the two 
parameters in the model correspond to biologically and physically relevant phenomena, it should be 
expected that they create trends commensurate with the characteristics of the sub-populations. n, the 
effective degrees of freedom in the system, is a more physically-based parameter, while λ0, a 
representation of the aggressiveness of the malignant cells, is a more biologically-based parameter. A 
larger λ0 with n held constant corresponds to a higher death rate, as can be expected, but a lower n 
with a constant λ0 contributes to a higher death rate as well. The increasing λ0 with increasing size 
and grade is consistent with the correlation between these two prognostic factors and mortality [28]. 
It is interesting to observe opposite trends for size and grade with respect to n, however. One 
possible explanation may be that with increasing pathological grade, cells become less differentiated, 
and consequently increase the effective degrees of freedom in the system due to less specific 
interactions.    
 
0 50 100 150 200 250 300
0
0.005
0.01
0.015
Time (months)
P
ro
ba
bi
lit
y 
di
st
rib
ut
io
n 
fu
nc
tio
n
0 50 100 150 200 250 300
0  
0.1
0.2
0.3
0.4
0.5
0.6
Time (months)
K
ap
la
n-
M
ei
er
 d
ea
th
 ra
te
Ductal
Lobular
Ductal
Lobular
 
Figure 7. The probability distribution functions using the parameters found in Table 1 are plotted on 
the left for two histological types: ductal and lobular. The corresponding Kaplan-Meier death rate 
curves are shown on the right for comparsion. This illustrates the influence of the two parameters 
on the shape of the resulting distribution. Ductal has a higher λ0 value which increases its death rate 
early on, but lobular has a lower n, which causes it to catch up and exceed the death rate for ductal.   
 
 
Discussion 
Superstatistics allows one to powerfully characterize fat tails at long times and distances, a hallmark 
of complex non-equilibrium systems.  In cancer-specific survival data, the tail of the frequency 
distribution decays as an exponential of the square root of time. It has been shown that power-law 
decays naturally emerge when the fluctuating intensive parameter is χ2 distributed [19], whereas our 
data here indicate an inverse χ2 distributed parameter. Of course, other possibilities exist as well, for 
example when microscopic contributions to an intensive parameter are multiplicative, in which case 
the intensive parameter will be lognormally distributed [19-21]. We have demonstrated here for the 
first time the existence of a complex system that is well described by inverse-χ2 superstatistics.  
 
The derivation of a dimension parameter for the network of spread pathways was based on a 
physical argument. It may be plausible to invoke a biological argument, saying that the network of 
spread pathways is instead the result of different classes of biochemical mediators. For example, 
factors involved in the induction of angiogenesis and growth factors involved in proliferation may 
create two distinct ‘pathways’ a cell may interact upon on its way to become a distant metastasis. 
Regardless, either formulation of this network leads to an effective dimensional parameter due to 
correlations, but how it arises will require actual experimental studies.  
 
This paper has attempted to characterize the dynamical reasons for the emergence of the observed 
cancer disease-specific mortality probability distributions. One interesting hypothesis for how the 
distribution comes about is the hypothesis that surgical treatment induces wound-healing responses 
that removes inhibitors of angiogenesis and stimulates production of mitogenic growth factors [29, 
30]. This will in turn accelerate the development of dormant distant micrometastases, and lead to a 
peak hazard a couple of years after surgical treatment. Although it could be a contributor to the 
statistics of the system, in effect reducing the expected times to spread, there can be a number of 
other contributors as well. The overall statistics of the cancer system is likely to be the result of the 
complex interaction between biological factors and physical factors that influence the dynamics of 
the underlying mechanisms, rather than any single factor alone. For other models dealing with 
survival-time statistics of cancer patients, see [31-37]. 
 
The analysis presented here is based on only the breast cancer data subset, but the extendibility of 
the model to other cancer subtypes will be a topic for future studies. There have already been hints 
to the existence of a ‘universal’ descriptor for cancer growth [7], and its survival distributions [37]. 
Computational modeling of cancer as a complex non-equilibrium system will help us gain additional 
insights into its underlying mechanisms, which allows us to better predict outcomes, ultimately 
leading to incrementally better therapeutic options for the cancer patient. 
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